Prime Only Members-Only Article

President Plays Pitchman For Another Experimental COVID ‘Cure’

This Week in the Swamp: A weekly dive into the muck of the Trump administration.
TARRYTOWN, NEW YORK, UNITED STATES - 2020/10/02: View of Corporate and Research and Development Headquarters of Regeneron Pharmaceuticals, Inc. on Old Saw Mill River Road. As President Donald Trump contracted COVID-19 he has been administered a dose of experimental Regeneron treatment, according to a memorandum from the President's physician. According to company press release antibody cocktail REGN-COV2 showing it reduced viral load and the time to alleviate symptoms in non-hospitalized patients with COVID-19. REGN-COV2 is a combination of two monoclonal antibodies (REGN10933 and REGN10987) and was designed specifically to block infectivity of SARS-CoV-2, the virus that causes COVID-19. (Photo by Lev Radin/Pacific Press/LightRocket via Getty Images)
TARRYTOWN, NEW YORK, UNITED STATES - 2020/10/02: View of Corporate and Research and Development Headquarters of Regeneron Pharmaceuticals, Inc. on Old Saw Mill River Road. As President Donald Trump contracted COVID-1... TARRYTOWN, NEW YORK, UNITED STATES - 2020/10/02: View of Corporate and Research and Development Headquarters of Regeneron Pharmaceuticals, Inc. on Old Saw Mill River Road. As President Donald Trump contracted COVID-19 he has been administered a dose of experimental Regeneron treatment, according to a memorandum from the President's physician. According to company press release antibody cocktail REGN-COV2 showing it reduced viral load and the time to alleviate symptoms in non-hospitalized patients with COVID-19. REGN-COV2 is a combination of two monoclonal antibodies (REGN10933 and REGN10987) and was designed specifically to block infectivity of SARS-CoV-2, the virus that causes COVID-19. (Photo by Lev Radin/Pacific Press/LightRocket via Getty Images) MORE LESS
By
|
October 8, 2020 6:07 p.m.

Something just… doesn’t smell right about the President’s use, and subsequent pitch campaign, for a fairly new and experimental COVID-19 therapy. 

This is a members-only article
Small Team. Big Results.
We’re proud of what our small newsroom has accomplished and it’s not hyperbole when we say that without our members, none of this would be possible.
Become a TPM Member
Free memberships available for students and those experiencing financial hardship.
Already a member? SIGN IN
Masthead Masthead
Founder & Editor-in-Chief:
Executive Editor:
Managing Editor:
Associate Editor:
Investigations Desk:
Reporters:
Editor at Large:
General Counsel:
Publisher:
Head of Product:
Director of Technology:
Associate Publisher:
Front End Developer:
Senior Designer: